Borchmann, P., Ferdinandus, J., Schneider, G., Moccia, A., Greil, R., Hertzberg, M., . . . Diehl, V. (2024). Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): A randomised, multicentre, parallel, open-label, phase 3 trial. The lancet, 404(10450), . https://doi.org/10.1016/S0140-6736(24)01315-1
Chicago-Zitierstil (17. Ausg.)Borchmann, Peter, et al. "Assessing the Efficacy and Tolerability of PET-guided BrECADD Versus EBEACOPP in Advanced-stage, Classical Hodgkin Lymphoma (HD21): A Randomised, Multicentre, Parallel, Open-label, Phase 3 Trial." The Lancet 404, no. 10450 (2024). https://doi.org/10.1016/S0140-6736(24)01315-1.
MLA-Zitierstil (9. Ausg.)Borchmann, Peter, et al. "Assessing the Efficacy and Tolerability of PET-guided BrECADD Versus EBEACOPP in Advanced-stage, Classical Hodgkin Lymphoma (HD21): A Randomised, Multicentre, Parallel, Open-label, Phase 3 Trial." The Lancet, vol. 404, no. 10450, 2024, https://doi.org/10.1016/S0140-6736(24)01315-1.